Viral Vector Design, Packaging & Optimization Webinar

Added:

Non-Viral Gene Delivery Systems

While viral vectors are highly efficient for gene delivery, they possess inherent drawbacks, including immunogenicity, limited cargo capacity, high manufacturing costs, and potential safety concerns like insertional mutagenesis. A significant counterpoint and alternative paradigm is the study and application of non-viral gene delivery systems. This field focuses on synthetic and natural biomaterials, such as lipid nanoparticles (LNPs), polymer-based vectors, and physical delivery methods like electroporation. Non-viral methods offer advantages such as lower immunogenicity, virtually unlimited genetic cargo size, safer transient expression profiles, and easier, more cost-effective scalability. Understanding non-viral alternatives is essential for a balanced view of the gene therapy landscape, highlighting that viral delivery is not the only—or always the safest—pathway to therapeutic gene modification.

Fundamental concepts of recombinant DNA technology, including plasmid design, promoters, transgenes, and molecular cloning techniques.
Basic virology principles, specifically the structures and life cycles of common viruses used in gene therapy, such as Lentivirus, Adenovirus, and Adeno-Associated Virus (AAV).
Standard mammalian cell culture techniques, including transfection methods (e.g., transient transfection using calcium phosphate or PEI) and the biology of packaging cell lines like HEK293.
The central dogma of molecular biology, specifically gene expression regulation, transcription factor binding, and translation initiation.
Downstream processing and purification strategies for viral vectors, such as ultracentrifugation, tangential flow filtration (TFF), and chromatography.
Advanced analytical characterization assays for quality control, including digital droplet PCR (ddPCR) for genome titer and ELISA for capsid titer.
Immunogenicity and host immune responses to viral vector administration, and strategies to evade or suppress pre-existing neutralizing antibodies.
Good Manufacturing Practice (GMP) standards, scale-up bioprocessing, and regulatory pathways for clinical-grade gene therapy products (FDA/EMA approvals).
15.7K views182likes40:23@abmgoodOriginal Release: 2019-06-19

This webinar covers the comprehensive workflow for designing, running, and optimizing viral gene delivery experiments, including selecting appropriate viral vectors (lentivirus, adenovirus, AAV, retrovirus, HSV, baculovirus) based on experimental goals such as stable vs. transient expression, cell type compatibility, and insert size; designing custom systems with appropriate promoters (CMV, EF1α, PGK), reporters (GFP, RFP), and expression types (overexpression, knockdown, CRISPR-Cas9); safely packaging viruses using multi-generational safety systems (first, second, third generation); calculating viral titers using qPCR-based methods; and optimizing MOI through systematic titration experiments to achieve efficient transduction while minimizing cytotoxicity.